Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Commercial Sponsor
BeiGene Australia Pty Ltd, Lymphoma Study Association
Scientific Title
A Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma